WA-YI-TECHNOLOGY
Photokina 2016 – YI Technology , a leading, international provider of advanced, intelligent imaging technologies, today introduced the YI M1 Mirrorless Digital Camera, its first professional-grade camera. The YI M1 is a mirrorless, interchangeable lens camera that features Bluetooth® connectivity and a simple app interface, offering the power and features of a professional camera with the ease and connectivity of a smartphone. YI will unveil the YI M1 at Photokina 2016, September 20-25 in Cologne, Germany.
This Smart News Release features multimedia. View the full release here: http://www.businesswire.com/news/home/20160919006602/en/
“With the launch of the YI M1, we are aiming to re-energize professional quality photography by making it accessible and simple to use for the average person or amateur photographer,” said Sean Da, CEO and Co-Founder of YI Technology. “Our mission is to bring top of the line technology to professionals and beginners alike in a simple, easy-to-use form and the YI M1 is no exception.”
Stunning Image and Video Quality
The YI M1 offers the ultimate image and video quality capturing 20 megapixel still images and stunning 4K video at 30 frames per second. It features the latest SONY IMX269 Image Sensor, supports ISO up to 25,600, as well as 2000-megapixel and Wide Dynamic Range video. Two lens options include a 12-40mm F3.5-5.6 and 42.5mm F1.8. YI M1 also includes an MFT mount system, which is compatible with more than 50 interchangeable lenses.
Simple, User-Friendly Design
Inspired by the ease of a smartphone, the simple yet sophisticated design of the YI M1 means photographers of any level, from beginner to professional, can capture and share stunning video and images. It features a 3-inch LCD touch screen, intuitive design and comprehensive controls. The lightweight and compact design means the user can focus more on shooting and less on heavy equipment. With the “Master Guide” feature in the accompanying YI M1 App, users can access photography templates, composition guidelines and step-by-step instructions, to shoot like a professional.
Easy Sharing and Connectivity
Built-in WiFi and Bluetooth technology offer users a way to seamlessly connect to a smartphone for fast sharing to social networks.
Pricing & Availability
YI M1 Mirrorless Camera will be available soon in two colors, Ice Silver and Storm Black. US and European pricing and availability will be announced soon on YITechnology.com.
To view the YI M1 in person at Photokina 2016 in Cologne, Germany, please visit YI Technology booth A-032, Hall 09.1.
About YI Technology:
YI Technology is a leading, international provider of advanced, intelligent imaging technologies, products, services and platforms. Its development team consists of industry-leading experts from the US, China, Japan, Israel and Europe with several decades of combined experience in imaging technology, algorithms, data analysis, cloud computing and mobile applications. YI is committed to using innovative technology to make everyday life safer, richer and more fun.
YI believes that the very best imaging and sensing technology should be easy to use and accessible to everyone. With the company’s passion, hard work and commitment to combining the highest quality technology solutions with great value, YI aims to provide millions of users of all ages from every corner of the world with peace of mind, and inspire greater connections between families, friends and communities. For more information visit www.yitechnology.com .
Find and like us on social media:
www.youtube.com/c/YIcamera
www.facebook.com/yitechnologyofficial
https://twitter.com/yitechnology
https://www.instagram.com/yitechnology/
View source version on businesswire.com: http://www.businesswire.com/news/home/20160919006602/en/
Contact:
Blanc & Otus for YI Technology
Jennifer Pierce, 415-856-5152
Jennifer.pierce@blancandotus.com
pr@yitechnology.com
Link:
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Vertex Receives CHMP Positive Opinion for ALYFTREK®, a New Once-Daily CFTR Modulator for the Treatment of Cystic Fibrosis28.4.2025 08:03:00 CEST | Press release
- ALYFTREK®(deutivacaftor/tezacaftor/vanzacaftor) recommended for people with CF ages 6 years and older with at least one non-class I mutation in the CFTR gene -- In head-to-head clinical trials, deutivacaftor/tezacaftor/vanzacaftor was non-inferior on ppFEV1 and superior compared to KAFTRIO® (ivacaftor/tezacaftor/elexacaftor) at reducing sweat chloride - Vertex Pharmaceuticals (Nasdaq: VRTX) today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion for ALYFTREK®(deutivacaftor/tezacaftor/vanzacaftor)for the treatment of people with cystic fibrosis (CF) ages 6 years and older who have at least one non-class I mutation in the cystic fibrosis transmembrane conductance regulator (CFTR) gene. “Our goal has always been to serially innovate to help people with cystic fibrosis live healthier and longer lives. If approved, this new medicine would be indicated for people with CF ages 6 years and older with at least
Prilenia Enters into a Collaboration and License Agreement with Ferrer for the Commercialization and Co-Development of Pridopidine in Europe and Other Select Markets28.4.2025 07:02:00 CEST | Press release
-- Total deal size of approximately €500 million, including approximately €125 million in upfront and near-term milestones ---- Ferrer to commercialize pridopidine in Europe and other select markets; Prilenia retains full commercialization and development rights to pridopidine in North America, Japan and Asia Pacific ---- Co-development agreement in the territory supports further expansion of pridopidine in Huntington’s disease, amyotrophic lateral sclerosis and future indications ---- Pridopidine for Huntington’s disease is currently under review by the European Medicines Agency (EMA) with a CHMP opinion expected in the second half of 2025 -- Prilenia Therapeutics B.V., a biopharmaceutical company driven by an unwavering commitment to scientific excellence and accelerating progress for people affected by Huntington’s disease (HD) and amyotrophic lateral sclerosis (ALS), today announced that it has entered into a collaboration and license agreement with Ferrer for the commercialization
Ferrer Enters Into a Collaboration and License Agreement With Prilenia for the Commercialization and Co-Development of Pridopidine28.4.2025 07:00:00 CEST | Press release
Ferrer, an international B Corp pharmaceutical company with an increasing focus on rare neurological diseases, and Prilenia Therapeutics B.V.,a clinical-stage biotech company, have announced the signing of a strategic co-development and license agreement in which Ferrer obtains the rights to develop, manufacture and commercialize Pridopidine in the European Region, the Middle East and North African Region, the Southern African Region, the Central and South American Region, and the Commonwealth of Independent States Region. Pridopidine, a potent and highly selective, orally administered sigma-1 receptor agonist, designed to regulate key neuroprotective mechanisms that are often impaired in neurodegenerative diseases, is a promising candidate for the treatment of Huntington’s Disease (HD), a rare inherited neurodegenerative disease, with a high unmet medical need1. It has been studied in more than 1,700 people and long-term safety data of up to 7 years duration are available from previou
Innorna Announces FDA Rare Pediatric Disease and Orphan Drug Designations Granted to IN013 for Treatment of Wilson Disease27.4.2025 11:36:00 CEST | Press release
Innorna, a clinical-stage biotechnology company revolutionizing mRNA therapeutics with its innovative lipid nanoparticle (LNP) delivery technology, today announced the U.S. Food and Drug Administration (FDA) has granted both Rare Pediatric Disease Designation (RPDD) and Orphan Drug Designation (ODD) to its investigational mRNA therapy, IN013, for treating Wilson Disease (WD). This dual achievement accelerates the clinical development of IN013, advancing Innorna’s mission to deliver transformative therapies for WD patients. About FDA Designations The Rare Pediatric Disease Designation (RPDD) incentivizes therapies for serious or life-threatening diseases affecting fewer than 200,000 U.S. patients, primarily those aged 18 or younger. Sponsors may qualify for a Priority Review Voucher (PRV) upon approval to expedite FDA review of a subsequent drug application. The Orphan Drug Designation (ODD) supports therapies targeting rare diseases (affecting fewer than 200,000 U.S. patients) by provi
Everen Specialty Appoints Carla Greaves Chief Underwriting Officer25.4.2025 19:00:00 CEST | Press release
Everen Specialty, a Bermuda-based (re)insurer for energy markets worldwide, today announced the appointment of Carla Greaves as its new Chief Underwriting Officer (CUO). This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250425273777/en/ Carla Greaves Ms. Greaves will join the Executive Leadership Team of the Everen Group, based in the Bermuda office, later this year. She succeeds Jane Peterson, Interim CUO, who will continue in a consultancy capacity to facilitate the transition. With more than 30 years of underwriting and leadership experience in the (re)insurance industry, Ms. Greaves brings a wealth of expertise and a proven track record of success in the Casualty market where she is recognized for building high-performing teams, driving profitable growth, and successfully navigating complex market environments. Prior to joining Everen Specialty, Ms. Greaves held increasingly senior leadership positions, most recently servin
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom